Xiao-Rong Yang
Overview
Explore the profile of Xiao-Rong Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang F, Wei X, Yang M, Lu C, Yang X, Deng J, et al.
Thorac Cancer
. 2025 Feb;
16(4):e70025.
PMID: 39994841
Background: The epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) has a unique "cold" immune profile. DNA damage repair (DDR) genes are closely related to tumorigenesis and...
2.
Guan M, Yu L, Gu H, Fu Q, Liu M, Li K, et al.
Int J Biol Macromol
. 2025 Feb;
306(Pt 1):141270.
PMID: 39984106
As the global population ages, cognitive decline in older adults has gained significant attention in public health, underscoring the urgent need for effective intervention strategies. This study investigates the impact...
3.
Yang X, Zhong S, Jin Z, Gao X, Wu Y, Zhou Q, et al.
Transl Lung Cancer Res
. 2024 Dec;
13(11):3224-3240.
PMID: 39670004
Background: Epidermal growth factor receptor () and mesenchymal-epithelial transition () gene mutations are well established in the pathogenesis of non-small cell lung cancer (NSCLC). However, there is limited understanding about...
4.
Yu L, Liu M, Guan M, Wang R, Yang X, Zhang X, et al.
Immun Ageing
. 2024 Nov;
21(1):81.
PMID: 39543616
Cognitive decline is a critical hallmark of brain aging. Although aging is a natural process, there is significant heterogeneity in cognition levels among individuals; however, the underlying mechanisms remain uncertain....
5.
Deng J, Yang M, Yang X, Chen Z, Xu C, Zhou Q
BMC Cancer
. 2024 Sep;
24(1):1190.
PMID: 39333978
Background: Immune checkpoint inhibitors (ICIs) have become the recommended first-line treatment for advanced non-small cell lung cancer (NSCLC) without driver gene mutations. However, data on the failure patterns of first-line...
6.
Liu S, Yan L, Wang H, Ding Z, Liu H, Zhang X, et al.
Oncologist
. 2024 Jun;
29(11):e1425-e1434.
PMID: 38940446
Backgrounds: There is little evidence on the safety, efficacy, and survival benefit of restarting immune checkpoint inhibitors (ICI) in patients with cancer after discontinuation due to immune-related adverse events (irAEs)...
7.
Wei X, Lu C, Zhang Y, Fan X, Xu C, Chen Z, et al.
Oncoimmunology
. 2024 Apr;
13(1):2340154.
PMID: 38601319
Metabolism reprogramming within the tumor microenvironment (TME) can have a profound impact on immune cells. Identifying the association between metabolic phenotypes and immune cells in lung adenocarcinoma (LUAD) may reveal...
8.
Luo W, Mei S, Huang Z, Chen Z, Zhang Y, Yang M, et al.
J Transl Med
. 2024 Apr;
22(1):326.
PMID: 38566102
Background: The effects of gut microbiota and metabolites on the responses to immune checkpoint inhibitors (ICIs) in advanced epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer (NSCLC) have...
9.
Liu Y, Xie W, Xi P, Zhang Z, Chen R, Fu S, et al.
Phytomedicine
. 2023 Dec;
123:155249.
PMID: 38056144
Background: Astaxanthin (AST) is a natural compound with anti-inflammatory/immunomodulatory properties that has been found to have probiotic properties. However, the role and mechanism of AST in chronic prostatitis/chronic pelvic pain...
10.
Pan Y, Zhang J, Gao X, Chen Z, Yan B, Tan P, et al.
Cancer Cell
. 2023 Oct;
41(10):1763-1773.e4.
PMID: 37816331
The value of circulating tumor DNA (ctDNA) during chemoradiotherapy (CRT) remains unclear but is critical for detecting molecular residual disease (MRD). In this prospective study, we sequenced 761 blood samples...